Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Here's Why This Analyst Cut Price Target On Regeneron

  • RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating.
  • Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment.
  • The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose data, expected in 2H 2022, would need to be impressive to defend fully vs. biosimilars. 
  • According to RBC, Phase 2 data showed consistent signals of anatomical and visual acuity efficacy advantages for 8mg vs. 2mg Eylea without any notable safety liability.
  • But KOL feedback suggests these differences may be subtle, and physicians are likely already using Eylea 2mg less frequently than the Q8W being tested in the Phase 3 control arm. Also, safety has yet been entirely de-risked. 
  • This gives a 70% probability of success.
  • Also Read: FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy.
  • Ultimately, RBC forecasts $6.2 billion in 2022 branded U.S. Eyelea sales (vs. $6.1 billion consensus), declining to a probability-blended $4.2 billion by 2026 (vs. $4.7 billion consensus).
  • RBC says that the R&D engine is robust operating leverage that should enable meaningful EPS pull-through on the success of evolving cancer/genetics pipeline long-term. 
  • Still, it remains unclear whether these assets or COVID-19 antibody revival can provide upward inflection. 
  • Price Action: REGN shares are down 1.44% at $649.63 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.